PRISM MarketView Showcases BioStem Technologies: Impressive Revenue Growth and Strategic Expansion
June 17 2024 - 10:17AM
PRISM MarketView presents an exclusive interview with Jason
Matuszewski, CEO of BioStem Technologies, Inc. (OTC: BSEM).
Following a successful start to 2024, the biotechnology company has
seen substantial revenue growth and is making significant strides
towards consolidating its debt, pursuing a potential uplisting to a
senior stock exchange, and launching pivotal clinical trials.
BioStem Technologies reported a remarkable increase in
first-quarter revenues to $41.9 million in 2024, up from $600,000
in the same period last year, marking a pivotal milestone in the
company's financial performance. "The first quarter of 2024 has
been phenomenal," Jason Matuszewski, CEO of BioStem, explained. The
company has also transitioned into a net positive equity position,
reporting positive net income on a US GAAP basis for the first
time.
Looking ahead, BioStem is focused on sustainable growth by
expanding its product offerings and geographical presence in the
hospital wound care and other medical settings. "Our strategic
direction is clear as we move towards 2025," Matuszewski added.
One of the key strategic goals for BioStem is the uplisting to a
senior stock exchange. "An uplisting to a senior exchange has
always been a crucial goal for us," Matuszewski stated. BioStem has
completed a rigorous two-year audit to meet the high standards
required by senior exchanges and is actively preparing for this
transition.
BioStem is set to initiate clinical trials in the second half of
the year to showcase the effectiveness of its products in
real-world clinical settings. "We recently announced our intention
to launch two clinical trials to evaluate the effectiveness of our
products," Matuszewski explained.
The full interview with Jason Matuszewski can be found at: PRISM
MarketView BioStem Technologies – Soaring Revenues and Strategic
Expansion
About BioStem Technologies:
BioStem Technologies Inc. (BSEM) is a leading regenerative
medicine company focused on the development, manufacture, and
commercialization of placental-derived biologics. The Company is
focused on manufacturing products that change lives, leveraging its
proprietary BioREtain processing method. BioREtain has been
developed by applying the latest research in regenerative medicine,
focused on maintaining growth factors and preserving tissue
structure. BioStem Technologies' quality management system and
standard operating procedures have been reviewed and accredited by
the American Association of Tissue Banks ("AATB"). These systems
and procedures are established per current Good Tissue Practices
("cGTP") and current Good Manufacturing Processes ("cGMP"). Our
portfolio of quality brands includes AmnioWrap2™, VENDAJE®, VENDAJE
AC®, and VENDAJE OPTIC®. Each BioStem Technologies placental
allograft is processed at the Company's FDA registered and AATB
accredited site in Pompano Beach, Florida. For more information,
please visit: http://www.biostemtechnologies.com
Forward-Looking Statements: Except for
statements of historical fact, this release also contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements relate to expectations or forecasts of future events.
Forward-looking statements may be identified using words such as
"forecast," "intend," "seek," "target," "anticipate," "believe,"
"expect," "estimate", "plan," "outlook," and "project" and other
similar expressions that predict or indicate future events or
trends or that are not statements of historical matters.
Forward-looking statements with respect to the operations of the
Company, strategies, prospects and other aspects of the business of
the Company are based on current expectations that are subject to
known and unknown risks and uncertainties, which could cause actual
results or outcomes to differ materially from expectations
expressed or implied by such forward-looking statements. These
factors include, but are not limited to: (1) the impact of any
changes to the reimbursement levels for the Company's products; (2)
the Company faces significant and continuing competition, which
could adversely affect its business, results of operations and
financial condition; (3) rapid technological change could cause the
Company's products to become obsolete and if the Company does not
enhance its product offerings through its research and development
efforts, it may be unable to effectively compete;(4) to be
commercially successful, the Company must convince physicians that
its products are safe and effective alternatives to existing
treatments and that its products should be used in their
procedures; (5) the Company's ability to raise funds to expand its
business; (6) the Company has incurred significant losses since
inception and may incur losses in the future; (7) changes in
applicable laws or regulations; (8) the possibility that the
Company may be adversely affected by other economic, business,
and/or competitive factors; (9) the Company's ability to maintain
production of its products in sufficient quantities to meet demand;
and (10) the COVID-19 pandemic and its impact, if any, on the
Company's fiscal condition and results of operations; You are
cautioned not to place undue reliance upon any forward-looking
statements, which speak only as of the date made. Although it may
voluntarily do so from time to time, the Company undertakes no
commitment to update or revise the forward-looking statements,
whether as a result of new information, future events or otherwise,
except as required by applicable securities laws.
About PRISM MarketView:
Established in 2020,
PRISM MarketView is dedicated to the monitoring and analysis of
small cap stocks in burgeoning sectors. We deliver up-to-the-minute
financial market news, provide comprehensive investor tools and
foster a dynamic investor community. Central to our offerings are
proprietary indexes that observe emerging sectors, including
biotech, clean energy, next-generation tech, medical devices and
beyond. Visit us at prismmarketview.com and follow us
on Twitter.
PRISM MarketView does not provide investment advice.
DisclaimerThis communication was produced by
PRISM MarketView, an affiliate of PCG Advisory Inc., (together
"PCG"). PCG is not a registered or licensed broker-dealer nor
investment adviser. No information contained in this communication
constitutes an offer to sell, a solicitation of an offer to buy, or
a recommendation of any security. PCG may be compensated by
respective clients for publicizing information relating to its
clients’ securities. See www.pcgadvisory.com/disclosures.
Contact:
PRISM MarketViewinfo@prismmarketview.com
646-863-6341